Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524012 | 0.94 | F10 (0.36) | F10CCR2ITGB3ITGA2BCHRM1 | |
| SCHEMBL3523459 | 0.92 | L3MBTL1 (0.35) | F10TSHRGRM2ITGB3ITGA2B | |
| SCHEMBL3525099 | 0.90 | GRM2 (0.37) | RAB9AGRM2CHRM1 | |
| SCHEMBL3524540 | 0.90 | F10 (0.40) | F10ABCB11ITGB3ITGA2B | |
| SCHEMBL6822916 | 0.90 | F10 (0.40) | F10ABCB11ITGB3ITGA2B | |
| SCHEMBL6823337 | 0.89 | PARP1 (0.35) | F10SMN1; SMN2CHRM1CETP | |
| SCHEMBL3526042 | 0.89 | PARP1 (0.35) | F10SMN1; SMN2CHRM1CETP | |
| SCHEMBL3522663 | 0.86 | TSHR (0.35) | F10NPC1TSHRRAB9ACHRM1 | |
| SCHEMBL3521790 | 0.85 | ALDH1A1 (0.35) | F10NPC1CHRM1 | |
| SCHEMBL3522293 | 0.85 | F10 (0.41) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | F10 4391/4885CCR2 3938/4885ABCB11 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.